GRITSTONE ONCOLOGY INC's ticker is GRTS and the CUSIP is 39868T105. A total of 89 filers reported holding GRITSTONE ONCOLOGY INC in Q2 2023. The put-call ratio across all filers is 0.45 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $491,639 | +6.4% | 285,837 | +20.7% | 0.00% | – |
| Q2 2023 | $461,932 | -75.7% | 236,888 | -65.4% | 0.00% | – |
| Q1 2023 | $1,903,180 | +19.4% | 684,597 | +48.2% | 0.00% | – |
| Q4 2022 | $1,593,562 | +271.5% | 461,902 | +176.8% | 0.00% | – |
| Q3 2022 | $429,000 | -10.6% | 166,900 | -15.9% | 0.00% | – |
| Q2 2022 | $480,000 | -65.2% | 198,486 | -40.7% | 0.00% | – |
| Q1 2022 | $1,378,000 | -88.1% | 334,733 | -62.7% | 0.00% | – |
| Q4 2021 | $11,550,000 | +40.1% | 898,008 | +17.6% | 0.00% | – |
| Q3 2021 | $8,247,000 | +1037.5% | 763,622 | +860.8% | 0.00% | – |
| Q2 2021 | $725,000 | +610.8% | 79,479 | +635.9% | 0.00% | – |
| Q1 2021 | $102,000 | +75.9% | 10,800 | +7.9% | 0.00% | – |
| Q1 2020 | $58,000 | -38.9% | 10,008 | -9.5% | 0.00% | – |
| Q3 2019 | $95,000 | -67.9% | 11,054 | -58.4% | 0.00% | – |
| Q2 2019 | $296,000 | – | 26,600 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 3,561,150 | $6,125,178 | 3.26% |
| Redmile Group, LLC | 8,509,126 | $14,635,697 | 0.70% |
| Avidity Partners Management LP | 2,733,800 | $4,702,136 | 0.19% |
| Frazier Life Sciences Management, L.P. | 1,430,878 | $2,461,110 | 0.16% |
| Artia Global Partners LP | 95,170 | $163,692 | 0.07% |
| Worth Venture Partners, LLC | 43,772 | $75,288 | 0.04% |
| SkyOak Wealth, LLC | 60,875 | $104,705 | 0.03% |
| Point72 Asset Management, L.P. | 5,924,867 | $10,190,771 | 0.03% |
| CORNERCAP INVESTMENT COUNSEL INC | 76,811 | $132,115 | 0.02% |
| Houlihan Financial Resource Group, Ltd. | 20,000 | $38 | 0.02% |